Here's Why Repligen Rose 33.6% in the First Half of 2020
Shares of Repligen (NASDAQ: RGEN) rose nearly 34% in the first half of 2020, according to data provided by S&P Global Market Intelligence. The bioprocess leader designs and manufactures equipment and tools required to produce biological drugs including monoclonal antibodies, gene therapies, and cell therapies. While the coronavirus pandemic has forced uncertainty onto many businesses, the company's unique niche has allowed it to buck broader trends and continue on its impressive growth trajectory.
